Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
SELECTA BIOSCIENCES INC (SELB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/17/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/17/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics"
08/14/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/12/2023 SC 13G Artal International S.C.A. reports a 6.6% stake in Selecta Biosciences, Inc.
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/04/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT"
03/21/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint",
"Slide Presentation of Selecta Biosciences, Inc."
03/02/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A MANGROVE PARTNERS reports a 6% stake in Selecta Biosciences, Inc.
01/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease",
"Selecta Biosciences Provides Business Update and Outlook for 2023",
"January 2023 Selecta Biosciences Corporate Presentation SELB 2Selecta Biosciences Investor Presentation"
12/14/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/18/2022 8-K Investor presentation
Docs: "2022 PLACEHOLDER FOR SPLASH PAGE"
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
08/22/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF"
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Investor presentation
Docs: "2022 PLACEHOLDER FOR SPLASH PAGE"
08/04/2022 8-K Quarterly results
Docs: "Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update"
07/27/2022 SC 13G MANGROVE PARTNERS reports a 5.4% stake in Selecta Biosciences, Inc.
06/30/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/23/2022 SC 13G MANGROVE PARTNERS reports a 5.1% stake in Selecta Biosciences, Inc.
05/18/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy